Triple-Drug attack aims to beat rare lymphoma

NCT ID NCT07457177

Not yet recruiting Disease control Sponsor: LIANG WANG Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tests a combination of three drugs—golidocitinib, pegaspargase, and an immunotherapy—as a first treatment for advanced NK T-cell lymphoma, a rare and aggressive cancer. The study will enroll 40 people who have not had prior therapy. The goal is to see if this combo can shrink tumors and improve survival, while monitoring for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Golidocitinib (a JAK inhibitor), pegaspargase (a chemotherapy drug), and an anti-PD-1 monoclonal antibody (an immunotherapy)
What this could lead to: If this works, it could offer a more effective first-line treatment for advanced NK T-cell lymphoma, potentially improving survival rates.
What could go wrong: This is an early phase 2 trial with only 40 participants, so results may not apply to everyone. The combination may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

extranodal nasal NK/T cell lymphoma Lymphoma, Extranodal NK-T-Cell mature T-cell and NK-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NK/T-CELL LYMPHOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.